Johnson & Johnson (NYSE:JNJ) Holdings Reduced by IFC Advisors LLC

IFC Advisors LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 62.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,955 shares of the company's stock after selling 4,873 shares during the period. IFC Advisors LLC's holdings in Johnson & Johnson were worth $490,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock valued at $33,666,460,000 after acquiring an additional 1,772,706 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Johnson & Johnson by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company's stock worth $8,321,881,000 after buying an additional 1,561,036 shares in the last quarter. Northern Trust Corp lifted its holdings in Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. Norges Bank acquired a new position in Johnson & Johnson in the 4th quarter worth $4,390,037,000. Finally, Wellington Management Group LLP lifted its holdings in Johnson & Johnson by 1.8% in the 4th quarter. Wellington Management Group LLP now owns 24,356,572 shares of the company's stock worth $3,522,447,000 after buying an additional 431,205 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded up $9.61 during trading on Wednesday, reaching $164.78. 22,128,650 shares of the company's stock traded hands, compared to its average volume of 8,142,964. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a 50 day moving average of $153.80 and a 200-day moving average of $154.64. The stock has a market capitalization of $396.47 billion, a P/E ratio of 18.33, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. The company's revenue for the quarter was up 5.8% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 3.16%. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a report on Thursday, July 10th. Finally, Raymond James Financial cut their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $171.00.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.